Anaplastic thyroid carcinoma (ATC) accounts for only 1 to 2% of all thyroid carcinomas, but it is one of the most lethal neoplasms in humans. To obtain further insights into this "orphan disease," we have es- Moreover, the ATCCJ has conducted an investigator-initiated, nationwide, prospective clinical trial since 2012; namely, the feasibility, safety and efficacy study of weekly paclitaxel administration for patients with ATC (UMIN: 000008574). Revised Japanese guidelines for treatment of thyroid tumors are going to adopt the recommendations from the results of this research. Since 2016, the ATCCJ has started the phase II study assessing the efficacy and safety of lenvatinib, a newly developed tyrosine kinase inhibitor for ATC (UMIN: 000020773). Our nationwide clinical trial network will strengthen the activity to recruit orphan disease patients and may discover new strategies to conquer this dismal malignancy in the near future. (J Nippon Med Sch 2018; 85: 18 27) 
Introduction
Anaplastic thyroid carcinoma (ATC) is uncommon and represents only 1 2% of all thyroid carcinomas, but accounts for 14 39% of thyroid cancer deaths 1, 2 . ATC is one of the most lethal neoplasms in humans, with a dismal prognosis as 5 20% of one-year survival. The aggressive nature and rarity of this disease make it difficult to improve the quality of evidence with regard to ATC. So far, most existing knowledge about ATC is derived from single-institution studies with limited numbers of cohorts and short-term follow-up. To obtain further insights into this "orphan disease", we established the ATC Research Consortium of Japan (ATCCJ) in January 2009. Objectives of the multi-institutional collaborative study group were (1) to create a multi-center database that accumulates all information for ATC available in Japan, (2) to carry out retrospective studies that analyze the big data, (3) to conduct prospective studies including clinical trials to evaluate controversial or novel strategies, and (4) to revise guidelines based on new evidence. Our ultimate goal is to improve the treatment outcome of patients with ATC.
To date, 67 institutions have taken part in the ATCCJ and over 1,200 cases have been registered in its database.
The ATCCJ has reported several retrospective studies using the database to upgrade evidence about the management of ATC. In addition, we have conducted In this review, we introduce our achievements and future directions to conquer this dismal malignancy.
Overall Treatment Outcomes for ATC
In 2012, we reported the treatment outcomes of a cohort of 677 ATC patients treated at 38 institutions during the 14-year period between 1995 and 2008 3 . Thirty-three patients for whom diagnosis was not achieved by pathological or cytological examination (i.e., only by clinical presentation) were excluded from the study. Clinical varieties of ATC were classified into the 4 following types:
common type (n=547); incidental type (n=29); anaplastic transformation at the neck lymph node(s) (n=95); and at a distant site (n=6). Incidental ATC was largely differentiated thyroid carcinoma (DTC) accompanied by a minute (1 2 cm) region of ATC, and anaplastic transformation type was ATC at a site other than the thyroid gland, which was associated with previous or concomitant DTC at the thyroid.
Survival curves for each clinical type of ATC are shown in Figure 1 . As for 547 patients with common type ATC, there were 208 males and 339 females (1 : 1.6) and mean age was 68.7±11.0 years (range: 28 to 100).
Their mean survival time (MST) was 113 days (range: 1 to 4,174) and 6-months and 1-year cause-specific survival (CSS) rate were 36% and 18%, respectively. Patients with incidental ATC showed significantly better outcomes than other types (p<.0001). Survival for anaplastic transformation at the neck lymph node(s) was also better than that for common type (p=.0082). Anaplastic change at a distant site had the worst prognosis (p<.0001 compared to common type). it is justifiable to use the best supportive care and local disease control to maintain quality of survival and to prevent death from suffocation, dysphagia and bleeding, despite the lack of survival benefit. Here, super-radical surgery was defined as: (1) Treatment outcomes are shown in Figure 3 . MST and 1-year CSS were 315 days and 41% for group R; 129 days and 33% for group S; 136 days and 15% for group P; 101 days and 10% for group N, respectively. Patients in group R displayed the best survival outcomes and the difference between group R and groups P or N was significant (p<.0001). Patients in group S also showed significantly better survival than those in groups P (p=.03).
Prognostic Factors for Common
Survival rates in groups R and S were almost identical (p =.94). Among group S, 7 (30%) patients survived more than 1 year. For PI! 1 patients, 1-year CSS was 50%; whereas for PI" 2, it was 11% (p=.15). Permanent tracheostomy was significantly more frequent in group S (18 out of 23: 78%) than in other groups (p<.0001). After the curative surgery, 33 (67%) patients in group R received " 40 Gy of RTX and/or any kind of CTX; however, only 9 (39%) patients in group S had the adjuvant therapies. Two patients in group S died from surgical complications.
Aggressive surgery offers significantly better outcomes The clinico-pathological characteristics of incidental ATC were compared to common-type ATC ( Table 2) .
There was no difference in age between the 2 groups; but the percentage of females was significantly higher in those with incidental ATC. The tumor size was smaller, and patients with extrathyroidal invasion or distant metastasis were significantly fewer in the incidental ATC group than in the common-type ATC group. Most incidental ATCs coexisted with papillary thyroid carcinoma (PTC). They may represent an initial stage of anaplastic transformation from PTC to ATC.
As shown in Figure 1 , patients with incidental ATC showed significantly better survival than patients with common-type ATC (p<.001). One-year and 2-year CSS rate were 72% and 58%, respectively; however, nearly half (12 out of 25; 48%) of the patients died of the disease eventually.
Regarding treatment modalities for patients with incidental ATC, the outcome was better in those who under- 
Revised Japanese Guidelines for Treatment of ATC
Based on Upgraded Evidence "Japanese guidelines for treatment of thyroid tumor", which was edited by Japan Association of Endocrine Surgeons (JAES) and Japanese Society of Thyroid Surgery (JSTS), was published in 2010. The guidelines for ATC stated that it was not possible to present scientific evidence that would be a guide to treatment, because there had been few randomized or even prospective trials at that time. They proposed a simple algorithm for treatment of ATC (Fig. 4) 
.
Revised Japanese guidelines are set to be published in 2017. The algorithm will be reformed adopting some of the ATCCJ's accomplishments (Fig. 5) . For example, it will note individual therapeutic strategies for patients with ATC considering both the prognostic index and UICC staging, to differentiate cases that could benefit from an effort to prolong life and cases that should be switched to best supportive care. The ATCCJ is now planning to conduct several clinical trials to fill in blanks of the algorithm and establish standardized therapeutic strategy for ATC as follows: (1) 
